Global Bacteriophage Market Set to Reach USD 72.4 Million by 2035, Driven by Advancements in Targeted Infection Treatments | Future Market Insights, Inc.

The global bacteriophage market is gaining traction as a promising avenue for addressing antibiotic resistance and combating bacterial infections. Bacteriophages, or phages, are naturally occurring viruses that specifically target and infect bacteria, offering a potential alternative to traditional antibiotics. The market's growth is propelled by the rising concern over antibiotic-resistant bacteria, which pose a significant global health threat.

/EIN News/ -- NEWARK, Del, March 19, 2025 (GLOBE NEWSWIRE) -- The global bacteriophage market is poised for significant growth, with its valuation projected to rise from USD 49 million in 2025 to USD 72.4 million by 2035, expanding at a compound annual growth rate (CAGR) of 4.0% over the forecast period. The increasing focus on bacteriophage therapy as a viable alternative to antibiotics, coupled with innovations in agricultural disease control and phage-based biopesticides, is set to fuel market expansion.

Bacteriophages are used as a dietary supplement as they are known to reduce the risk of incidence of food born infections by Escherichia, Salmonella, and other gut pathogens. These dietary supplements contain a specific combination of bacteriophages that attacks particular organisms in the gut.

A Rising Alternative to Antibiotics

With the growing global challenge of antibiotic resistance, bacteriophage therapy has emerged as a promising alternative in the fight against bacterial infections. Phages—viruses that specifically target and eliminate bacteria—offer a highly targeted approach to infection control, reducing the risk of harming beneficial microbiota. This precise mechanism has garnered interest from healthcare researchers and pharmaceutical companies, accelerating investments in bacteriophage-based treatments.

Get Insights into Market Movements: Request a Sample Report! https://www.futuremarketinsights.com/report-sample#5245502d47422d3134343631

Expanding Applications in Agriculture

Beyond human healthcare, the bacteriophage market is witnessing increased adoption in agricultural disease management. As farmers seek sustainable and environmentally friendly solutions to combat bacterial plant and livestock infections, phage-based biopesticides have gained traction. These solutions provide effective pathogen control while mitigating the ecological concerns associated with chemical pesticides and antibiotics in livestock farming.

Surge in Research Investments

Governments, academic institutions, and private companies are significantly increasing investments in bacteriophage research to develop innovative therapies for drug-resistant bacterial infections. The surge in clinical trials and regulatory approvals for phage-based therapies is expected to play a pivotal role in market expansion over the next decade. Additionally, collaborations between biotechnology firms and healthcare providers are further fostering advancements in phage therapeutics.

Technological Advancements Driving Growth

The market is also benefiting from technological breakthroughs in bacteriophage development, including genome editing, synthetic biology, and phage engineering. These innovations enhance the efficacy and scalability of phage therapy, making it a more viable option for widespread medical and agricultural use. Researchers are also exploring personalized phage therapy, which tailors treatment to individual bacterial infections, ensuring greater therapeutic success.

Key Market Trends

• Increased Clinical Trials: Growing clinical validation of bacteriophage therapy for conditions such as chronic wounds, cystic fibrosis, and gastrointestinal infections.
• Regulatory Advancements: Progress in regulatory frameworks supporting the approval of phage-based therapeutics.
• Strategic Partnerships: Collaborations between biotech firms, pharmaceutical companies, and research institutions to fast-track product development.
• Adoption in Food Safety: Rising use of bacteriophages in food preservation and bacterial contamination control in the food processing industry.

Market Outlook Bacteriophage

As the global burden of antibiotic-resistant infections continues to escalate, the bacteriophage market presents a crucial solution for the future of infection treatment. With advancements in biotechnology, increased funding, and growing awareness, the market is expected to witness sustained expansion over the next decade.

Rising Demand for Market Data: Our Full Report Offers Deep Insights and Trend Analysis! https://www.futuremarketinsights.com/reports/bacteriophage-market

Key Takeaways Bacteriophage Industry

• The USA and South Korea are expected to experience the highest CAGR of 4.2% from 2025 to 2035, indicating strong market growth in these regions.
• The UK is projected to grow at a slightly lower rate of 3.9%, making it the slowest-growing market among the listed regions.
• The European Union (EU) is anticipated to expand at a 4.0% CAGR, reflecting steady market development.
• Japan is set to witness a 4.1% CAGR, demonstrating consistent growth in the region.
• Overall, these projections highlight a balanced growth pattern across major global economies, with South Korea and the USA leading the expansion.
  

"The escalating issue of antibiotic resistance has positioned bacteriophage therapy as a pivotal alternative in our therapeutic arsenal. The specificity of phages to target pathogenic bacteria without disrupting beneficial microbiota offers a significant advantage over broad-spectrum antibiotics. Moreover, the integration of phage-based solutions in agriculture and food safety not only enhances yield and shelf life but also aligns with the global shift towards sustainable and natural products." says Sabyasachi Ghosh Associate Vice President at Future Market Insights (FMI) analyst.

What Are The Key Opportunities For Bacteriophage Manufacturers?

Growing emphasis on research and development of drugs and therapies for infectious diseases is expected to create immense growth opportunities in the market. Rising interest in the development of drugs for applications such as infectious diseases and immunological disorders will further boost the market.

For instance, in June 2020, Microgen opened a Biological Research Centre for the study of bacteriophages. The main purpose of this center will be to improve treatment-and-prevention drugs being an alternative to antibiotics.

According to the World Health Organization, antibiotic-resistant infections could kill about 10 million people per year by 2050. There is a huge, unmet need in patients with bacterial infections, which are mostly very difficult to treat with traditional antibiotic therapy.

Increasing antibiotic resistance pathogen needs to be treated with bacteriophage. The rising prevalence of antibiotic resistance has surged the demand for phage therapy. For instance, In October 2021, Intralytix, Inc. received clearance from the USA Food and Drug Administration (FDA) for an Investigational New Drug (IND) application for its product ShigActive™.

What Are The Factors Restraining The Demand For Bacteriophage?

The high cost of bacteriophage treatment is the major factor limiting sales in the market. Due to the high cost of therapy, several healthcare facilities such as small hospitals & clinics in underdeveloped regions are not able to afford the treatment, restraining growth.

Low- to middle-income countries generate more revenue from antibiotics as compared to bacteriophage as they are cheaper and show immediate results. This is the major restraining factor for the market

Competitive Landscape: Bacteriophage Market

The bacteriophage market is driven by the growing challenge of antibiotic resistance, increasing demand for precision antimicrobial therapies, and expanding applications across food safety, animal health, and biotechnology. Innovations in bacteriophage-based therapeutics, customized phage cocktails targeting specific bacterial infectomes, and advancements in phage engineering are shaping the industry's future. Companies in this space are focused on research-driven solutions to combat bacterial contamination and antibiotic-resistant infections in medical, agricultural, and industrial sectors.

Key Market Players Bacteriophage Industry

• Life Extension
• Arthur Andrew Medical
• Deerland Probiotics & Enzymes Inc.
• BioChimpharm
• Micreos Human Health
• Designs for Health
• Accelerated Health Systems LLC
• The Biostation
• Microgen
• IntraLytix Inc.

Comprehensive analysis of the life science & biotechnology industry—global trade dynamics, market potential, future outlook, and cutting-edge innovations across 20+ countries. https://www.futuremarketinsights.com/industry-analysis/life-science-and-biotechnology

Key Segmentation Bacteriophage Industry

By Product Type:

• Phage Probiotics
• Phage Therapeutics

By Route of Administration:

• Oral
• Topical
• Other
  

By Application:

• Gastroenterology
• Respiratory Infections Market
• Skin Infection Treatment
• Wound Prophylaxis
• Urogenital Infection Treatment
• Others

By Distribution Channel:

• Retail Pharmacies
• Hospital Pharmacies
• Online Pharmacies
  

Region:

• North America
• Europe
• Latin America
• Asia Pacific
• The Middle East and Africa
  

Explore FMI’s Related Ongoing Coverage on Healthcare Domain:

The cellular reprogramming tools market size is projected to reach USD 446.8 Million in 2025 and is expected to grow to USD 741.9 Million by 2035, registering a CAGR of 5.2% over the forecast period.

The global sales of whole plasmid sequencing are estimated to be worth USD 636.2 million in 2025 and are anticipated to reach a value of USD 1,548.2 million by 2035. Sales are projected to rise at a CAGR of 9.3% over the forecast period between 2025 and 2035. The revenue generated by whole plasmid sequencing in 2024 was USD 582.1 million.

The global antibody purification service market share is poised for significant growth, with its market size projected to expand from USD 1.2 billion in 2025 to USD 3.3 billion by 2035, registering a robust compound annual growth rate (CAGR) of 10.6% during the forecast period. The increasing adoption of monoclonal antibodies, advancements in bioprocessing technologies, and the growing biopharmaceutical industry are key factors propelling this expansion.

The antibody therapy market demand is set for substantial growth between 2025 and 2035, driven by increasing advancements in biopharmaceutical research, rising prevalence of chronic diseases, and growing demand for targeted therapies. The market is expected to reach USD 302.1 billion in 2025 and expand to USD 1,059.7 billion by 2035, reflecting a compound annual growth rate (CAGR) of 13.4% over the forecast period.

The antibody-mediated rejection prevention market growth is set for significant growth between 2025 and 2035, driven by advancements in transplant immunology, increasing organ transplant procedures, and rising prevalence of antibody-mediated rejection in transplant patients. The market is expected to reach USD 103.4 million in 2025 and expand to USD 613.7 million by 2035, reflecting a compound annual growth rate (CAGR) of 16% over the forecast period.

The airlift bioreactors market trends in 2025 stood at USD 2.96 Billion and will reach USD 8.20 Billion in 2035, at a CAGR of 10.7%. Increasing biopharmaceutical production, growing applications in cell culture-based vaccine manufacturing, and the demand for cost-effective bioprocessing solutions are some major factors driving market growth.

The global companion diagnostics market outlook is forecasted to attain USD 6,059.1 million by 2025, expanding at 6.8% CAGR to reach USD 11,682.8 million by 2035. In 2024, the revenue of this market was around USD 5,700.5 million.

The high content screening market overview is anticipated to grow from around USD 1.9 Billion in 2025, to USD 3.1 Billion by 2035, at a CAGR of 5.2% during the predicted years. High-content analysis (HCA) platforms are increasingly being embraced in research laboratories due to the need for rapid and efficient screening of potential drug candidates, toxicity determination, and imaging of cells.

The digital pathology market forecast will be near about USD 9.1 Billion in 2025 and USD 31.3 Billion in 2035, growing at a CAGR of 13.1% over the estimated period. The introduction of artificial intelligence and machine learning in digital pathology systems has improved diagnostic precision and workflows by allowing pathologists to process more information more efficiently.

The laboratory automation market analysis is expected to grow significantly from 2025 to 2035, as it will be worth about USD 2.5 billion in 2025, increase to over USD 6.3 billion at a 9.7% annual growth rate by 2035. High-throughput screening, microplate readers, and liquid-handling robots are all being favoured in the marketplace with the drive toward automated, miniaturized labs.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware - 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube